All In Biotech

NDA 021695 · Lupin

Antara (Micronized)

Fenofibrate · Oral · Peroxisome Proliferator Receptor alpha Agonist

Last checked: Nov 19, 2026Latest source record: Oct 1, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2004

Nov 30, 2004

Approved uses

2

Original approval plus efficacy supplements

Registered trials

211

64 Phase 3, 15 recruiting

FAERS reports

35,836

24,506 serious, 2,824 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 1, 2025.

Antara is indicated as adjunctive therapy to diet: to reduce triglyceride (TG) levels in adults with severe hypertriglyceridemia (TG greater than or equal to 500 mg/dL). to reduce elevated low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia when use of recommended LDL-C lowering therapy is not possible. Limitations of Use Markedly elevated levels of serum TG (e.g., > 2,000 mg/dL) may increase the risk of developing pancreatitis. The effect of fenofibrate therapy on reducing this risk has not been determined [see Warnings and Precautions ( 5.7 )] . Fenofibrate did not reduce coronary heart disease morbidity and mortality in two large, randomized controlled trials of patients with type 2 diabetes mellitus [ see Warnings and Precautions ( 5.1 ) and Clinical Studies ( 14.4 ) ]. Antara is a peroxisome proliferator-activated receptor (PPAR) alpha agonist indicated as an adjunct to diet: to reduce triglyceride (TG) levels in adults with severe hypertriglyceridemia (TG greater than or equal to 500 mg/dL) ( 1 ). to reduce elevated low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia when use of recommended LDL-C lowering therapy is not possible ( 1 ). Limitations of Use: Markedly elevated levels of serum TG (e.g., > 2,000 mg/dL) may increase the risk of developing pancreatitis. The effect of fenofibrate therapy on reducing this risk has not been determined ( 1 ). Fenofibrate did not reduce coronary heart disease morbidity and mortality in two large, randomized controlled trials of patients with type 2 diabetes mellitus ( 1 ).

Mechanism: The active moiety of Antara is fenofibric acid. The pharmacological effects of fenofibric acid in both animals and humans have been studied through oral administration of fenofibrate. The lipid-modifying effects of fenofibric acid seen in clinical practice have been explained in vivo in transgenic mice and in vitro in human hepatocyte cultures by the activation of PPAR alpha receptor. Through this mechanism, fenofibric acid increases lipolysis and elimination of triglyceride-rich particles from plasma by activating lipoprotein lipase and reducing production of apoprotein C-III (an inhibitor...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 21, 2005 Supplement 1 · Efficacy Letter
  • Nov 30, 2004 Original approval · Type 3 - New Dosage Form LabelReviewLetter
5 products under this application
  • ANTARA (MICRONIZED) · FENOFIBRATE 90MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · CAPSULE, ORAL · Discontinued
  • ANTARA (MICRONIZED) · FENOFIBRATE 130MG · CAPSULE, ORAL · Prescription · TE AB
  • ANTARA (MICRONIZED) · FENOFIBRATE 43MG · CAPSULE, ORAL · Prescription · TE AB
  • ANTARA (MICRONIZED) · FENOFIBRATE 30MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · CAPSULE, ORAL · Discontinued
  • ANTARA (MICRONIZED) · FENOFIBRATE 87MG · CAPSULE, ORAL · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Fenofibrate" as an intervention, any sponsor and status, largest first.

All 211 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue2,202
  • diarrhoea2,135
  • nausea2,066
  • drug ineffective1,826
  • headache1,583
  • dyspnoea1,561
  • off label use1,420
  • dizziness1,405
  • pain1,399
  • fall1,376
  • asthenia1,331
  • acute kidney injury1,288

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004264
2005257
2006404
2007311
2008482
2009553
2010670
2011971
20121,096
20131,084
20141,374
20152,216
20162,581
20172,513
20182,797
20192,729
20202,502
20212,269
20222,233
20232,161
20242,068
20252,335
20261,966

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 589 on PubMed

Sponsor: Lupin

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.